Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
IO Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, immune-modulating cancer therapies. The company operates within the biotechnology and oncology immunotherapy industries, with a core emphasis on therapeutic cancer vaccines designed to activate T cells against immune-suppressive targets in the tumor microenvironment. Its primary value proposition is the development of off-the-shelf peptide-based immunotherapies intended to be used in combination with existing immune checkpoint inhibitors.
The company’s lead product candidate is IO102/IO103, a dual-antigen therapeutic cancer vaccine targeting indoleamine 2,3-dioxygenase (IDO) and programmed death-ligand 1 (PD-L1). IO Biotech was founded in 2014 in Copenhagen, Denmark, as IO Biotech ApS and later established a U.S. holding company structure. The company completed its initial public offering in 2021 and is listed on the Nasdaq under the ticker IOBT, transitioning from a private research-focused organization to a publicly traded clinical-stage developer.
Business Operations
IO Biotech’s operations are centered on the research and clinical development of its proprietary immune-modulating therapeutic cancer vaccine platform. The company generates no commercial revenue and relies on equity financing to fund operations, with expenditures primarily related to clinical trials, manufacturing of clinical-grade materials, and research and development activities. Its lead clinical program, IO102/IO103, is being evaluated in multiple Phase 2 and Phase 3 clinical trials, including studies in melanoma and non-small cell lung cancer, primarily in combination with PD-1 inhibitors such as nivolumab.
Operationally, IO Biotech conducts clinical development through collaborations with clinical research organizations and academic cancer centers. The company retains ownership of its core intellectual property and peptide vaccine technology while leveraging external manufacturing partners for drug substance and drug product supply. IO Biotech ApS functions as a key operating subsidiary, housing much of the company’s scientific workforce and research infrastructure.
Strategic Position & Investments
Strategically, IO Biotech is focused on advancing IO102/IO103 through late-stage clinical development with the objective of achieving regulatory approval in its initial oncology indications. The company’s growth strategy emphasizes combination therapy approaches, positioning its vaccine platform as complementary to existing immune checkpoint inhibitors rather than competitive with them. This strategy is intended to de-risk development by aligning with established standards of care in oncology.
IO Biotech has not completed any transformative acquisitions and does not operate a diversified portfolio of subsidiaries or investments. Instead, capital is concentrated on internal pipeline development and clinical execution. Emerging areas of focus include expanding the therapeutic cancer vaccine platform into additional solid tumor indications, although further pipeline assets beyond IO102/IO103 remain in early research stages and are not yet clinically validated based on publicly available data.
Geographic Footprint
IO Biotech maintains a transatlantic operational presence, with corporate headquarters in New York, United States, and primary research and development activities based in Copenhagen, Denmark. This structure allows the company to access U.S. capital markets while leveraging Denmark’s established life sciences research ecosystem.
Clinical trials are conducted across North America and Europe, involving multiple countries through international oncology trial networks. While the company does not currently commercialize products in any region, its clinical and regulatory activities reflect a global development strategy targeting major pharmaceutical markets, including the United States and the European Union.
Leadership & Governance
IO Biotech is led by an executive team with experience in oncology drug development, immunology, and public-company operations. The leadership’s strategic vision centers on advancing immune-modulating cancer vaccines into late-stage development and establishing a differentiated role within combination immuno-oncology regimens.
Key executives include:
- Mai-Britt Zocca – President and Chief Executive Officer
- Mark Green – Chief Financial Officer
- Mads Hald Andersen – Founder and Chief Scientific Officer
- Qasim Ahmad – Chief Medical Officer
The board and management emphasize scientific rigor, disciplined capital allocation, and strategic partnerships as core governance principles. Data inconclusive based on available public sources regarding any formally articulated leadership philosophy beyond these stated strategic priorities.